Barclays Cuts Certara (NASDAQ:CERT) Price Target to $14.00

Certara (NASDAQ:CERT) had its price target lowered by Barclays from $16.00 to $14.00 in a research report released on Tuesday morning, Benzinga reports. The brokerage currently has an equal weight rating on the stock.

CERT has been the subject of several other reports. JMP Securities restated a “market perform” rating on shares of Certara in a research note on Wednesday, July 10th. UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price on the stock in a research report on Friday, September 27th. Robert W. Baird decreased their price target on shares of Certara from $19.00 to $18.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Finally, KeyCorp cut their price target on shares of Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $17.08.

Certara Stock Up 3.1 %

Shares of Certara stock opened at $11.57 on Tuesday. Certara has a twelve month low of $10.35 and a twelve month high of $19.87. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of -29.67, a price-to-earnings-growth ratio of 5.40 and a beta of 1.49. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.28. The company has a fifty day moving average price of $11.64 and a 200 day moving average price of $14.46.

Certara (NASDAQ:CERT) last announced its earnings results on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The company had revenue of $93.31 million for the quarter, compared to analysts’ expectations of $96.01 million. During the same quarter in the previous year, the business posted $0.10 earnings per share. The business’s quarterly revenue was up 3.2% compared to the same quarter last year. Equities research analysts forecast that Certara will post 0.27 earnings per share for the current fiscal year.

Insider Buying and Selling at Certara

In other news, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the sale, the insider now directly owns 50,091 shares in the company, valued at approximately $552,503.73. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the sale, the insider now owns 99,704 shares in the company, valued at approximately $1,125,658.16. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the transaction, the insider now owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Blue Trust Inc. bought a new stake in shares of Certara during the second quarter valued at about $26,000. Innealta Capital LLC bought a new stake in shares of Certara during the 2nd quarter worth about $36,000. Intech Investment Management LLC acquired a new stake in shares of Certara in the 2nd quarter worth approximately $152,000. Algert Global LLC bought a new position in shares of Certara in the second quarter valued at approximately $156,000. Finally, MQS Management LLC acquired a new position in shares of Certara during the second quarter valued at approximately $162,000. Institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.